BioCentury | Dec 2, 2020
Distillery Therapeutics

Oligodendrocyte-derived extracellular vesicles for multiple sclerosis

...DISEASE CATEGORY: Autoimmune diseaseINDICATION: Multiple sclerosis (MS)Extracellular vesicles derived from oligodendrocytes could prevent and treat MS. The...
...from the supernatant of mature oligodendrocytes differentiated from mouse oligodendrocyte progenitor cells. In mouse models of MS...
...cells, and an immunosuppressive profile in monocytes and monocyte-derived dendritic cells. In other mouse models of MS...
BioCentury | Oct 21, 2020
Product Development

Aducanumab looms larger after Biogen cuts guidance, shelves programs in MS and SMA

As Biogen revealed the submission of its Alzheimer’s therapy aducanumab to regulators in a second major territory, a series of other disclosures in its 3Q20 earnings announcement suggest its reliance on the mAb for future...
BioCentury | Oct 16, 2020
Deals

With Disarm deal, Atlas returns to Lilly to take neuro program forward

...inhibitors for peripheral neuropathy and neurological diseases including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).Chairman...
BioCentury | Oct 13, 2020
Finance

Chord launches with $16M to test MS drug cladribine in rare autoimmune disorders

...developed as an oral tablet by the EMD Serono unit of Merck KGaA (Xetra:MRK) for MS...
...Merck revived the program and finally had Mavenclad cladribine approved by FDA last year for MS.Chord...
...warning for an increased risk of malignancies and teratogenicity. But as is the case in MS...
BioCentury | Oct 2, 2020
Distillery Therapeutics

IL-12B monomers to treat multiple sclerosis, rheumatoid arthritis

...By Claire Quang, Staff Writer DISEASE CATEGORY: Autoimmune diseaseINDICATION: Multiple sclerosis (MS); rheumatoid arthritis (RA)Monomers of...
...dimerize with itself, IL-12A or IL23P19, could treat autoimmune disorders including MS and RA. Relapsing-remitting MS...
...and lower serum levels of IL-12B monomer than healthy, age-matched volunteers. In mouse models of MS...
BioCentury | Sep 26, 2020
Politics, Policy & Law

Warp Speed’s Slaoui expects two COVID-19 vaccines this year, rebuts Sen. Warren

...initiative that wouldn't have happened in its absence?MS...
...how will you know that you're done? MS...
...or authorized —for both vaccines and therapies?MS...
BioCentury | Sep 22, 2020
Finance

Medicxi adds firepower for maturing portfolio via first secondary fund

Medicxi has established a new secondary fund to invest in a set of maturing companies originally backed by the firm’s predecessor organization, while offering liquidity and a reinvestment opportunity as options for LPs in the...
BioCentury | Sep 10, 2020
Product Development

AZ trial pause brings unconfirmed link between vaccines, demyelinating syndromes back into spotlight

...whether vaccines of all stripes are linked to CNS demyelinating syndromes such as transverse myelitis, MS...
BioCentury | Sep 9, 2020
Product Development

Roche’s Anderson wants industry to keep its foot on the gas for infectious disease, post-pandemic: a BioCentury audio interview

...is what is reasonable? [00:18:10] So for example, we launched a major innovative therapy in MS...
BioCentury | Sep 9, 2020
Product Development

Data Bytes: Btk race in MS heats up as Roche enters Phase III

...last month (see “Via $3.4B Principia Takeout, Sanofi Can Explore Potential of Btk Inhibitor Beyond MS”).According...
...a timeline.  TARGETSBtk – Bruton’s tyrosine kinase Stephen Hansen fenebrutinib (GDC-0853, RG7845) PRN2246, SAR442168 evobrutinib (M2951, MSC2364447C) Sanofi Merck KGaA Autoimmune Multiple sclerosis (MS...
Items per page:
1 - 10 of 4027